Onkologie-VirtuOS

Roche Onkologie VirtuOS

Scandic Berlin Potsdamer Platz, Berlin

Agenda für Sonntag, den 05.06.2016

Uhrzeit Programm
13:00 – 14:45 Uhr

Virtual ASCO

  • Breast Cancer
    • Joint Analysis of the ABC (Anthracyclines in Early Breast Cancer) Trials (USOR 06-090, NSABP B-46I/USOR 07132, NSABP B-49 [NRG Oncology]) Comparing Docetaxel Plus Cyclophosphamide (TC) to Anthracycline/Taxane-Based Chemotherapy Regimens (TaxAC) in Women with High-Risk, HER2-Negative Breast Cancer (Joanne Lorraine Blum)
    • PANTHER: Prospective Randomized Phase III Trial of Tailored and Dose-Dense Versus Standard Tri-Weekly Adjuvant Chemotherapy for High-Risk Breast Cancer in the Modern Era of Endocrine and Anti-HER2 Therapy (Jonas C. S. Bergh)
    • A Prospective Analysis of Surgery and Survival in Stage IV Breast Cancer (TBCRC 013) (Tari A. King)
  • Targeted Therapy in Brain Metastases: Ready for Prime Time? (Manmeet Singh Ahluwalia)
  • Developmental Therapeutics-Immunotherapy and Tumor Biology
    • Correlation of peripheral and intratumoral T-cell receptor (TCR) clonality with clinical outcomes in patients with metastatic urothelial cancer (mUC) treated with atezolizumab. (Samuel Funt MD)
14:45 – 15:15 Uhr Pause
15:15 – 16:15 Uhr

Diskussion mit Experten (Live-Satellitenschaltung nach Chicago)

  • Schwerpunkt Hämatologie (Prof. Topp, Würzburg und Prof. Heß, Mainz)
  • Schwerpunkt Gynäkologie (Prof. Mahner, München und Prof. Hilpert, Hamburg)
16:15 – 18:00 Uhr

Virtual ASCO

  • Hematologic Malignancies
    • Targeted Therapy in Chronic Lymphocytic Leukemia: Where are we now? (Jennifer R. Brown)
    • Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial). (Michele Cavo)
    • Phase 1b/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive Patients Aged 65 Years with Acute Myelogenous Leukemia (Tara L. Lin)
    • Treatment-Free Remission in Patients with CML-CP Treated with Frontline Nilotinib: Results From the ENESTfreedom Study (Andreas Hochhaus)
  • Lung Cancer and Pancreatic Cancer
    • Checkmate 032: Nivolumab Alone or in Combination with Ipilimumab for the Treatment of Recurrent Small Cell Lung Cancer (Scott Joseph Antonia)
    • CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. (Matthew David Hellmann)
    • Localized Pancreatic Cancer: Multidisciplinary Management with Incorporation of ASCO Guidelines (Gabriela Chiorean)
18.15 – 18.30 Uhr Abschlussdiskussion

Agenda für Montag, den 06.06.2016

Uhrzeit Programm
8:30 – 10:35 Uhr

Virtual ASCO

  • Genitourinary Cancer
    • Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/metastatic urothelial carcinoma (mUC): Primary analysis of IMvigor210 cohort 1. (Arjun Vasant Balar)
    • Updated efficacy from IMvigor210: Atezolizumab in platinum treated locally advanced/metastatic urothelial carcinoma (mUC). (Robert Dreicer)
    • Long-term overall survival with nivolumab in previously treated patients with advanced renal cell carcinoma (aRCC) from phase I and II studies. (David M. McDermott)
    • ARv7 As a Clinical Biomarker in CRPC (Emmanuel S. Antonarakis)
  • Gastrointestinal Cancer
    • Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients. (Jerome Galon)
    • Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. (Michael J. Overman)
10:35 – 11:05 Uhr Pause
11:05 – 11:20 Uhr
  • The relationship between primary tumor sidedness and prognosis in colorectal cancer. (Deborah Schrag)
11:20 - 13:00

Virtual ASCO

  • Sarcoma
    • Pazopanib vs pazopanib + gemcitabine in refractory soft tissue sarcoma: A randomized phase II trial of the AIO. (Hans-Joachim Schmoll)
    • Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue (STS) and bone sarcomas (BS): Results of SARC028—A multicenter phase II study. (Hussein Abdul-Hassan Tawbi)
  • Hematologic Malignancies
    • Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): CASTOR study. (Antonio Palumbo)
    • Two years rituximab maintenance vs. observation after first-line treatment with bendamustine plus rituximab (B-R) in patients with mantle cell lymphoma: First results of a prospective, randomized, multicenter phase II study (a subgroup study of the StiL NHL7-2008 MAINTAIN trial). (Mathias J. Rummel)
    • Effect of bortezomib on complete remission (CR) rate when added to bendamustine-rituximab (BR) in previously untreated high-risk (HR) follicular lymphoma (FL): A randomized phase II trial of the ECOG-ACRIN Cancer Research Group (E2408). (Andrew M. Evans)
13:00 – 14:00 Uhr Mittagspause
14:00 – 15:00 Uhr

Diskussion mit Experten (Live-Satellitenschaltung nach Chicago)

  • Schwerpunkt Gastrointestinale Tumore (Prof. Seufferlein, Ulm; Prof. Kubicka, Reutlingen)
  • Schwerpunkt Immuntherapie (Prof. Weichert, München; PD Dr. Reinmuth, Gauting und Prof. Grünwald, Hannover)
15.00 – 16.00 Uhr

Virtual ASCO

  • Lung Cancer and Tumor Biology
    • Safety and efficacy of single-agent rovalpituzumab tesirine (SC16LD6.5), a delta-like protein 3 (DLL3)-targeted antibody-drug conjugate (ADC) in recurrent or refractory small cell lung cancer (SCLC). (Charles M. Rudin)
    • CONVERT: An international randomised trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS). (Corinne Faivre-Finn)
    • PD-1/PD-L1 As Predictive Biomarkers: Where Do We Stand? (Padmanee Sharma)
16.00 - 16.30 Pause
16:30 – 17:45 Uhr

Virtual ASCO

  • Breast and Gynecologic Cancer
    • A randomized trial (MA.17R) of extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen in postmenopausal women with early-stage breast cancer. (Paul E. Goss)
    • Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis. (Jonathan A. Ledermann)
    • Phase 2 study of everolimus, letrozole, and metformin in women with advanced/recurrent endometrial cancer. (Pamela T. Soliman)
    • How Much Is Too Much? (Steven Cohen)
17.45 – 18.00 Uhr Abschlussdiskussion

Agenda für Dienstag, den 07.06.2016

Uhrzeit Programm
8:30 – 10:30 Uhr

Virtual ASCO

  • Highlights of the Day
    • Central Nervous System Tumors (Wolfgang Wick)
    • Head and Neck Cancer (Robert I. Haddadd)
  • Where Does the Truth Lie in Immune Biomarker Development? (Suzanne Louise Topalian)
  • Breast Cancer
    • Bone Modifying Agents in Breast Cancer (William John Gradishar)
    • You Again? (Kathy D. Miller)
    • Redefining Targets in Triple-Negative Breast Cancer (Ruth O`Regan)
10:30 – 11:00 Uhr Pause
11:00 – 12:15 Uhr

Virtual ASCO

  • Gastrointestinal Cancer
    • FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma. (Salah Eddin Al-Betran)
    • Challenging the Status Quo in Esophagogastric Cancer (Peter C. Enzinger)
    • ESPAC-4: A multicenter, international, open-label randomized controlled phase III Trial of Adjuvant Combination Chemotherapy of Gemcitabine (GEM) and Capecitabine (CAP) Versus Monotherapy Gemcitabine in Patients with Resected Pancreatic Ductal Adenocarcinoma (John P. Neoptolemos)
    • A Multicenter Randomized Phase III Trial of Neo-Adjuvant Chemotherapy Followed by Surgery and Chemotherapy or by Surgery and Chemoradiotherapy in Resectable Gastric Cancer: First Results from the CRITICS Study (Marcel Verheij)
12:15 – 13:15 Uhr Mittagspause
13:15 – 13:45 Uhr

Diskussion mit Experten (Live-Satellitenschaltung nach Chicago)

  • Schwerpunkt Lungenkrebs (Prof. Reck, Großhansdorf und Dr. Dickgreber, Rheine)
13:45 – 14:45 Uhr

Virtual ASCO

  • Lung Cancer
    • Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study. (Hiroshi Nokihara)
  • Melanoma
    • Great Debate: The BRAF-Positive Patient-Immunotherapy Is the First Option (Antoni Ribas)
  • Value Frameworks in Oncology (Deborah Schrag)
14:45 – 15:15 Uhr

Pause

15:15 – 15:45 Uhr

Diskussion mit Experten (Live-Satellitenschaltung nach Chicago)

  • Schwerpunkt Brustkrebs (Prof. Schneeweiss, Heidelberg und Prof. Müller, Hamburg)
15.45 – 16.00 Uhr Abschlussdiskussion und Verabschiedung